Slump In Generic Submissions Helps US FDA Draw Nearly Even With Approvals
Agency Publishes Data For First Half Of Current Fiscal Year
Executive Summary
ANDA approval rates have remained steady, while submission rates dropped compared to prior years.
You may also be interested in...
ANDA Approval Decline Continues, But Why?
US FDA says COVID disruptions may be having an impact; complete response letters have also dropped significantly.
FDA Guides On Virtual Inspections During COVID-19
Details of how the FDA plans to conduct remote evaluations of manufacturing facilities during the COVID-19 pandemic have been set out in guidance published by the US agency.
Remote Site Visits Will Help US FDA Keep Reviews On Track During Remainder Of Pandemic
Video facility tours expected to help clear way for timely drug and biologic approvals while COVID-19 still prevents inspections.